Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07497958
Starting soon Not applicable

Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy

NCT07497958 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-sen University
Phase
Not applicable
Started
2026-04-01
Last updated
2026-03-27

Condition(s) studied

Renal Cell Carcinoma (RCC)Renal Function Abnormal

Investigational drug(s) / intervention(s)

Ischemic preconditioningNO ischemic preconditioning

Ischemic preconditioning: One day before the surgery, use a sphygmomanometer to apply pressure to the patient's upper limb to 200mmHg for 5 minutes, then reduce the pressure to 0mmHg for 5 minutes, repeating this process for a total of 3 cycles. On the second day, perform a routine partial nephrectomy

NO ischemic preconditioning: Routine partial nephrectomy

Study summary

It is demonstrated that remote ischemic preconditioning can alleviate the degree of acute renal injury on the operated side in patients undergoing partial nephrectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients who are scheduled to undergo partial nephrectomy, with no specific surgical procedure limitation, including laparoscopic surgery, robot-assisted surgery, and open surgery * Aged 18 to 80 * Possess good organ function status: sufficient organ function (based on the normal values of the clinical trial center) 1. Blood routine test: WBC≥3.5×10\^9/L, absolute neutrophil count ≥1.5×10\^9/L, PLT≥75.0×10\^9/L, HGB≥80g/L; 2. Liver function: Total bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN; Exclusion Criteria: * The anesthesiologist assesses that the patient cannot tolerate general anesthesia surgery * Individuals with severe cardiovascular and cerebrovascular diseases, uncontrolled hypertension, and diabetes * Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² * Horseshoe kidney * Solitary kidney * Pregnant women

Primary outcome measure(s)

  • AIRD spectrum score based on the patient's preoperative creatinine level and postoperative peak creatinine level — 2 weeks after partial nephrectomy
    The AIRD spectrum score was defined as: (observed peak SCr - SCr ideal-peak)/(SCr worstcase-peak - SCr ideal-peak） The range of this indicator should be between 0 and 1, with 0 and 1 representing two extreme situations. 0 indicates that the kidney on the operated side is completely undamaged, while 1 indicates that the kidney on the operated side has completely lost its function.

Trial sites (1)

FacilityCityRegionStatus
651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China Sun Yat-sen University Cancer Center Guangzhou Guangdong

More Sun Yat-sen University trials in China

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Active, not recruiting
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL Recruiting
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC Starting soon
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Enrolling by invitation
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Recruiting

Other trials for the same condition

Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study Enrolling by invitation
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma Recruiting
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC Recruiting
The Cold Ischemia Robot-assisted Partial Nephrectomy Recruiting
Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07497958 on ClinicalTrials.gov ↗ ← All trials in China